Watson launches first generic Lipitor
Stephen Foley is a former Associate Business Editor of The Independent, based in New York. He left in August 2012. In a decade at the paper, he covered personal finance, the UK stock market and the pharmaceuticals industry, and had also been the Business section's share tipster. Between arriving with three suitcases in Manhattan in January 2006 and his departure, he witnessed and reported on a great economic boom turning spectacularly to bust. In March 2009, he was named Business and Finance Journalist of the Year at the British Press Awards.
Thursday 01 December 2011
Watson Pharmaceuticals, the New Jersey-based drug manufacturer, did not even wait for dawn before trumpeting its first shipments yesterday of Lipitor, the cholesterol-lowering pill that became the world's biggest selling medicine.
After years of legal and scientific battles, Lipitor's creator Pfizer yesterday relinquished its stranglehold over production of the pill, as its patent on the drug in the US finally expired. And at 5.30am, Watson announced it "began shipping the product today," and called it the "largest generic product launch in US history".
That claim is certainly true, since Lipitor, the brand name for atorvastatin calcium, still had $7.8bn (£5bn) sales in the year to September, after peaking at $10.7bn last decade. Millions of Americans pop the pills to keep their cholesterol under control and to reduce the risks of heart attacks and strokes.
But as well as being the biggest generic product launch, this is also proving to be the most unusual, as Pfizer works to maintain as big a chunk of Lipitor sales as possible. For starters, it is serving as the exclusive supplier of the medicine to Watson, at least until 2016, and it has also adopted a range of novel tactics to keep another rival, India's Ranbaxy, from taking market share. Since drugs with an estimated $80bn of sales will be going off-patent in the next two years, Pfizer is being closely watched by other pharmaceuticals giants, including GlaxoSmithKline and AstraZeneca in the UK.
Pfizer has tied up a series of deals with American health insurers and pharmacy chains to supply branded Lipitor at a discount. Generic copies typically price slightly lower than the original drug for a few months after patent expiry until additional manufacturers emerge. In deals with Medco and Express Scripts, two big pharmacy benefits managers, Pfizer has agreed to match the generics' prices.
It is also subsidising the amount consumers have to contribute to the cost of the medicine, so that Americans on Lipitor are not encouraged to switch. However, Pharmacists United for Truth and Transparency says it is a "blatant attempt" to keep health insurers paying for more expensive branded drugs.
- 1 Bruce Jenner's 'Interview of the year': Suicidal thoughts, rejection by family members and new wardrobe
- 2 Sofyen Belamouadden murder: The inside story of a crime that horrified Britain
- 3 How to turn off/stop 'seen by' on Facebook: Disable it to make your chats seem less passive aggressive
- 4 'We're not heroes, just tourists': Swedish police officers on holiday stop vicious assault on New York subway
- 5 Buckingham Palace guard who attacked passers-by in 'most most violent piece of CCTV footage' police officer had seen walks free
Top 20 misconceptions people believe are true
Sofyen Belamouadden murder: The inside story of a crime that horrified Britain
'We're not heroes, just tourists': Swedish police officers on holiday stop vicious assault on New York subway
Nepal earthquake: More than 1,100 killed across four countries and in Mount Everest avalanche
Australian student Tommy Connolly, 23, adopts his pregnant, homeless 17-year-old cousin to give her a chance at 'a better life'
The sickening truth about food banks that the Tories don't want you to know
Katie Hopkins on LBC: Listen to caller taking The Sun columnist to task over migrant comments
Migrant boat disaster: Ukip candidate mocks victims in sickening Twitter post
Nigel Farage wants the BBC to stop making programmes like Doctor Who, Strictly Come Dancing, and Top Gear
Global warming: Scientists say temperatures could rise by 6C by 2100 and call for action ahead of UN meeting in Paris
Rupert Murdoch berated Sun journalists for not doing enough to attack Ed Miliband and stop him winning the general election
iJobs Money & Business
£50000 - £55000 per annum: Ashdown Group: Business Analyst - Financial Service...
£18000 - £23000 per annum + OTE £45K: SThree: At SThree, we like to be differe...
£20000 - £25000 per annum + competitive: SThree: Did you know? SThree is the o...
£22000 - £24000 per annum: Recruitment Genius: This is an opportunity to join ...